Anti-inflammatory treatment after cataract surgery in Sweden: changes in prescribing patterns from 2010 to 2017

AimsTo investigate changes in the prescribing patterns of postoperative eye drops following cataract surgery in Sweden from 2010 to 2017.MethodsData from cataract procedures registered in the National Cataract Register during the month of March from 2010 to 2017 were record linked and sent to the Swedish Prescribed Drug Register, which allowed us to determine which eye drops the patients had obtained from 3 months presurgery to 2 weeks post surgery.ResultsDuring the 8-year study period, 54 889 surgeries were registered. Combination treatment with steroid and non-steroidal anti-inflammatory drug (NSAID) eye drops increased from 12% in 2010 to 60% in 2017 (p<0.001) while monotherapy with steroids decreased from 71% in 2010 to 26% in 2017 (p<0.001). Monotherapy with NSAIDs after surgery was fairly stable, at 17% in 2010 and 13% in 2017 (p<0.001). Combination treatment was more frequent in patients with diabetic retinopathy (p<0.001) or age-related macular degeneration (p<0.001), while monotherapy with steroids was more frequent in patients with glaucoma (p<0.001). The proportion of monotherapy or combination therapy varied widely between ophthalmic clinics. The prescription of antibiotic eye drops after surgery also varied greatly between clinics, from 0% to 63%, with a national average of 4.9%.ConclusionThere is a change in the prescription pattern of anti-inflammatory eye drops after cataract surgery in Sweden, with less monotherapy and an increasing proportion of patients receiving a combination of steroid and NSAID eye drops.

Download Full-text

Experience of the anti-inflammatory eye drops Ivinak®-solopharm use in patients after cataract surgery

Ophthalmology journal ◽

10.17816/ov79196 ◽

2021 ◽

Vol 14 (3) ◽

pp. 71-76

Author(s):

Iurii I. Pirogov ◽

Fedor N. Rozhdestvenskiy ◽

Polina A. Dzitstsoeva ◽

Aleksandra Y. Artiushenko

Keyword(s):

Visual Acuity ◽

Cataract Surgery ◽

Anterior Chamber ◽

Corneal Thickness ◽

Eye Drops ◽

Ocular Surface Disease Index ◽

Age Related ◽

Anti Inflammatory ◽

Chamber Fluid ◽

Number Of Cells

BACKGROUND: The prevalence of inflammatory complications that occur after phacoemulsification remains an unsolved problem. AIM: To analyze the results of the use of Ivinak-SOLOpharm eye drops containing 0.09% bromfenac solution in the complex of anti-inflammatory therapy in patients after cataract surgery in comparison with similar drugs from other manufacturers. MATERIALS AND METHODS: The study included 60 patients (60 eyes) with a diagnosis of age-related cataract, who underwent phacoemulsification. All patients were divided into 2 groups: in the first group, patients used Ivinac eye drops 3 days before surgery and 20 days after it; in the second group, patients used another similar drug containing 0.09% bromfenac solution according to an identical scheme. All patients underwent visual acuity testing and keratopachimetry before and after surgery. On Day 4 and Day 20 after surgery, the degree of inflammatory reaction of the eye was assessed by the number of cells in the anterior chamber fluid, subjective signs of inflammation in patients, using the OSDI (Ocular Surface Disease Index) questionnaire. RESULTS: When analyzing the obtained data, no statistically significant differences were found between the groups in terms of best corrected visual acuity, corneal thickness, number of cells in the anterior chamber fluid, and subjective symptoms of inflammation in patients. CONCLUSIONS: Ivinak-SOLOpharm has proven its effectiveness and safety in the perioperative prevention of inflammatory processes in phacoemulsification.

Download Full-text